Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Non-Current Liabilities: 2015-2024

Historic Total Non-Current Liabilities for Cartesian Therapeutics (RNAC) over the last 9 years, with Dec 2024 value amounting to $438.0 million.

  • Cartesian Therapeutics' Total Non-Current Liabilities fell 9.60% to $407.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $407.7 million, marking a year-over-year decrease of 9.60%. This contributed to the annual value of $438.0 million for FY2024, which is 0.07% down from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Total Non-Current Liabilities is $438.0 million, which was down 0.07% from $438.3 million recorded in FY2023.
  • Cartesian Therapeutics' 5-year Total Non-Current Liabilities high stood at $438.3 million for FY2023, and its period low was $52.9 million during FY2022.
  • Its 3-year average for Total Non-Current Liabilities is $309.7 million, with a median of $438.0 million in 2024.
  • In the last 5 years, Cartesian Therapeutics' Total Non-Current Liabilities crashed by 52.73% in 2022 and then soared by 728.24% in 2023.
  • Cartesian Therapeutics' Total Non-Current Liabilities (Yearly) stood at $154.7 million in 2020, then declined by 27.66% to $111.9 million in 2021, then tumbled by 52.73% to $52.9 million in 2022, then spiked by 728.24% to $438.3 million in 2023, then fell by 0.07% to $438.0 million in 2024.